Gilead’s Trodelvy Basks In TROPiCS With FDA Breast Cancer Nod
Company Lays Out Development Strategy In Q4 Earnings
Gilead’s big push into oncology bore more fruit with the FDA approval of Trodelvy based on the TROPiCS-02 trial. More development catalysts lie ahead for 2023, company said in its earnings.
